Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): Expanded efficacy and safety analyses from CheckMate 648.
Year: 2022
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Ian Chau, Jaffer A. Ajani, Yuichiro Doki, Jianming Xu, Lucjan Wyrwicz, Satoru Motoyama, Takashi Ogata, Hisato Kawakami, Chih-Hung Hsu, Antoine Adenis, Farid El Hajbi, Maria Di Bartolomeo, Maria Ignez Freitas Melro Braghiroli, Eva Holtved, Mariela A. Blum Murphy, Sandzhar Abdullaev, Samira Soleymani, Ming Lei, Ken Kato, Yuko Kitagawa
Institutions: Royal Marsden Hospital, The University of Texas MD Anderson Cancer Center, The University of Osaka, Academy of Military Medical Sciences, The Maria Sklodowska-Curie National Research Institute of Oncology, Akita University Hospital, Kanagawa Cancer Center, Kindai University, National Taiwan University Hospital, Institut Regional du Cancer de Montpellier, Centre Oscar Lambret, Fondazione IRCCS Istituto Nazionale dei Tumori, Universidade de São Paulo, Odense University Hospital, Bristol-Myers Squibb (United States), National Cancer Center Hospital, Keio University
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4281947098